低剂量达沙替尼治疗老年慢性期慢性髓性白血病患者(DAVLEC):一项单臂、多中心、2期试验
DAVLEC是一项在日本25家医院开展的多中心单臂2期试验,纳入52例70岁以上初诊慢性期慢性髓性白血病患者,一线给予达沙替尼20 mg/日(标准剂量的20%)。12个月时60%(31/52)患者达到主要分子学反应,23%(12/52)发生3-4级不良事件,中性粒细胞减少最常见(6%),无治疗相关死亡。作者认为20 mg/日可作为老年患者起始剂量考虑,但需在更大规模及更多样化人群中进一步研究。
要点
- 70岁以上初诊慢性期CML患者一线达沙替尼20 mg/日,12个月主要分子学反应率60%(31/52)。
- 3-4级不良事件发生率23%(12/52),中性粒细胞减少最常见(6%,3/52),无治疗相关死亡。
- 作者认为20 mg/日值得考虑作为老年患者起始剂量,但需更大规模及更多样化人群进一步研究。
核心结论
- 低剂量达沙替尼20 mg/日值得考虑作为70岁以上初诊慢性期慢性髓性白血病患者的起始剂量。
- 该剂量需在更大规模队列及更多样化人群中进一步研究。
研究设计与样本
- DAVLEC为多中心、单臂、2期试验,在日本25家医院开展。
- 纳入年龄大于70岁、初诊慢性期慢性髓性白血病、ECOG体能状态0-2、除4周内羟基脲外未接受过CML治疗的患者。
- 达沙替尼口服起始剂量为标准剂量的20%(20 mg/日);3、6、9个月评估为最佳反应且不良事件≤2级则维持原剂量,反应欠佳且不良事件≤2级则增加20 mg/日;因3级及以上不良事件减量后不再增加剂量;评估为失败(进展至加速期或急变期)则停药。
- 主要终点为12个月时达到主要分子学反应,采用符合方案分析。
- 2016年11月1日至2019年10月30日共52例患者接受一线达沙替尼20 mg/日治疗;诊断时中位年龄77.5岁(73.5-83.0),男性35例(67%),女性17例(33%)。
主要发现
- 12个月时52例中31例(60%)达到主要分子学反应(单侧95%CI 48-71),中位随访366天(IQR 353-372)。
- 12例(23%)患者报告3-4级不良事件;中性粒细胞减少最常见,发生于3例(6%)患者。
- 未观察到治疗相关死亡。
关键数值与推荐
- 主要终点12个月主要分子学反应率60%(31/52,单侧95%CI 48-71)。
- 3-4级不良事件发生率23%(12/52);中性粒细胞减少发生率6%(3/52)。
- 达沙替尼起始剂量为标准剂量的20%(20 mg/日);反应欠佳且不良事件≤2级时增加20 mg/日。
临床怎么用
- 作者认为低剂量达沙替尼20 mg/日值得考虑作为老年初诊慢性期CML患者的起始剂量。
- 作者指出该剂量需在更大规模队列及更多样化人群中进一步研究。
局限性
- 作者指出该剂量需在更大规模队列中进一步研究。
- 作者指出需在更多样化人群中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BCR-ABL1 tyrosine kinase inhibitors (TKIs) are commonly initiated in older patients with chronic myeloid leukaemia in the chronic phase at standard doses. However, because of their safety profile in this population, appropriate therapy has not been established. We aimed to investigate whether a lower than standard dose of dasatinib was an appropriate therapy for older patients with chronic myeloid leukaemia in the chronic phase. METHODS: DAsatinib, Very Low-dose, for Elderly CML-CP patients (DAVLEC) was a multicentre, single-arm, phase 2 trial done in 25 Japanese hospitals. We enrolled patients older than 70 years with newly diagnosed chronic myeloid leukaemia in the chronic phase, ECOG performance status 0-2, and no previous treatment for CML other than hydroxyurea within 4 weeks. Second-generation TKI dasatinib was given orally at a starting dose of 20% of the standard dose (20 mg/day). If the treatment was assessed as optimal response at 3 months, 6 months, and 9 months and adverse events were grade 2 or better (according to the NCI Common Toxicity Criteria v 4.0), the same dose was continued. If response was suboptimal and adverse events were grade 2 or better, the dose was increased by 20 mg/day. Once a dose reduction had been made because of a grade 3 or worse adverse event, there were no further dose increases. Treatment was discontinued if assessed as failure (disease progression to the accelerated phase or acute phase). The primary endpoint was the achievement of major molecular response at 12 months, assessed using a per-protocol analysis. This trial is registered at with the UMIN clinical trial registry, UMIN000024548, and has completed its planned observation period. FINDINGS: Between Nov 1, 2016, and Oct 30, 2019, 52 patients received first-line dasatinib therapy at 20 mg/day. The median age at diagnosis was 77·5 years (73·5-83·0). 35 (67%) patients were male and 17 (33%) were female. 31 (60%) of 52 patients reached major molecular response at 12 months (one-sided 95% CI 48-71), with a median follow-up of 366 days (IQR 353-372). Grade 3-4 adverse events were reported in 12 (23%) patients. Neutropenia was the most frequent grade 3-4 adverse event, occurring in three (6%) patients. No treatment-related deaths were observed. INTERPRETATION: Low-dose dasatinib at 20mg/day is worthy of consideration as a starting dose for older patients with newly diagnosed chronic myeloid leukaemia in the chronic phase. However, this dose needs to be further studied in a larger cohort and with a more ethnically diverse population. FUNDING: Bristol-Myers Squibb.
引用
- Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021. PMID: 34826413. doi:10.1016/S2352-3026(21)00333-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。